A few weeks ago, shares in GW Pharma lost a third of their value after UK regulators said they wanted more evidence about the drug's benefits.

Final approval in Canada should now be little more than a formality, analysts said, and the company expects full approval for Sativex early in 2005.

Despite hopes of regulatory approval last year, a series of delays has put back Sativex's launch in the UK.

Approximately 50,000 people in Canada have been diagnosed with MS and 85,000 people are suffering from the condition in the UK.

The latest news sent shares in GW Pharma up 8.5p, or 8.1%, to 113.5p.

